Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of atherosclerosis and thrombosis

• Publication date

  2016-05-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.5551/jat.32300PMID 26632165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibroblasts in post-infarction inflammation and cardiac repair.

  2013cited by this paper
• Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

  2011cited by this paper
• The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of Atherosclerotic Plaques

  2011cited by this paper
• Enhanced expression of plasminogen activator inhibitor may prevent cardiac rupture in female and castrated mice after myocardial infarction.

  2011cited by this paper
• Microvascular thrombosis: an exciting but elusive therapeutic target in reperfused acute myocardial infarction.

  2010cited by this paper
• Treatment of Acute Myocardial Infarction With Sirolimus-Eluting Stents Results in Chronic Endothelial Dysfunction in the Infarct-Related Coronary Artery

  2009cited by this paper
• A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart

  2009cited by this paper
• The ‘PAI-1 paradox’ in vascular remodelling

  2008cited by this paper
• RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection

  2008cited by this paper
• Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis

  2008cited by this paper
• Plasminogen activator inhibitor-1: The double-edged sword in apoptosis

  2008cited by this paper
• The Contributions of Integrin Affinity and Integrin-Cytoskeletal Engagement in Endothelial and Smooth Muscle Cell Adhesion to Vitronectin*

  2007cited by this paper
• Relation between transcardiac gradient of VEGF and coronary flow response in humans.

  2007cited by this paper
• Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction

  2007cited by this paper
• Down-regulation of Plasminogen Activator Inhibitor 1 Expression Promotes Myocardial Neovascularization by Bone Marrow Progenitors

  2004cited by this paper
• Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.

  2004cited by this paper
• Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1).

  2004cited by this paper
• Color of culprit lesion at 6 months after plain old balloon angioplasty versus stenting in patients with acute myocardial infarction.

  2004cited by this paper
• Impact of microvascular integrity and local viability on left ventricular remodelling after reperfused acute myocardial infarction

  2003cited by this paper
• Coronary Flow Velocity Pattern Immediately After Percutaneous Coronary Intervention as a Predictor of Complications and In-Hospital Survival After Acute Myocardial Infarction

  2002cited by this paper
• Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1

  2002cited by this paper
• Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death.

  2002cited by this paper
• Comparison of effects of losartan versus enalapril on fibrinolysis and coagulation in patients with acute myocardial infarction.

  2001cited by this paper
• Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.

  2001cited by this paper
• Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes.

  2001cited by this paper
• ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations

  2000cited by this paper
• Plasminogen-activator inhibitor type 1 and coronary artery disease.

  2000cited by this paper
• Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.

  1998cited by this paper
• Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.

  1998cited by this paper
• Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.

  1997cited by this paper
• The renin-angiotensin system and fibrinolysis.

  1997cited by this paper
• Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty.

  1995cited by this paper
• Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure

  1994cited by this paper
• Activation of neurohumoral systems in postinfarction left ventricular dysfunction.

  1993cited by this paper
• Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury.

  1991cited by this paper
• Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

  1988cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Plasminogen activator inhibitors.

  1987cited by this paper
• The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.

  1985cited by this paper
• Endothelial injury induced by thrombin or thrombi.

  1975cited by this paper

• Cardiac Tissue Damage in a Female Animal Post-COVID Model: Relevance of Chemokine-Mediated Inflammation

  2025cites this paper
• Associations of circulating adipokines and coronary artery disease in young adults

  2024cites this paper
• DYNAMICS OF THE LEVELS OF ASYMMETRIC DIMETHYLARGININE AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 IN PATIENTS WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS DEPENDING ON THE REPERFUSION STRATEGY

  2024cites this paper
• The Role of Selenium in Atherosclerosis Development, Progression, Prevention and Treatment

  2023cites this paper
• “Super” SERPINs—A stabilizing force against fibrinolysis in thromboinflammatory conditions

  2023cites this paper
• Human-umbilical cord matrix mesenchymal cells improved left ventricular contractility independently of infarct size in swine myocardial infarction with reperfusion

  2023cites this paper
• Associations of adipokines with coronary heart disease in young and middle-aged people

  2023cites this paper
• Novel Targets Regulating the Role of Endothelial Cells and Angiogenesis after Infarction: A RNA Sequencing Analysis

  2023cites this paper
• Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

  2022cites this paper
• Main molecular mechanisms for noncommunicable diseases

  2022cites this paper
• Therapeutic application of Sertoli cells for treatment of various diseases.

  2021cites this paper
• C-Peptide as a Therapy for Type 1 Diabetes Mellitus

  2021cites this paper
• Trans-myocardial blood Interleukin-6 levels relate to intracoronary imaging defined features of plaque vulnerability and predict procedure-induced myocardial infarction.

  2021cites this paper
• Effect and mechanism of plasminogen activator inhibitor-1 on cardiomyocytes apoptosis stimulated by palmitate

  2020cites this paper
• Significant decrease of von Willebrand factor and plasminogen activator inhibitor-1 by providing supplementation with selenium and coenzyme Q10 to an elderly population with a low selenium status

  2020cites this paper
• Circulating miR-146a in healthy aging and type 2 diabetes: Age- and gender-specific trajectories.

  2019cites this paper
• Nicotine exposure suppresses hyperinsulinemia and improves endothelial dysfunction mediators independent of corticosteroids in insulin-resistant oral contraceptive-treated female rats

  2018cites this paper
• MicroRNA-30b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor-1.

  2018cites this paper
• MicroRNA ‐ 30 b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor ‐ 1

  2018cites this paper
• Endothelial dysfunction of coronary arteries in subjects without diabetes: An association with both insulin resistance and impaired insulin secretion response.

  2018cites this paper
• Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments

  2017cites this paper
• Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression

  2017cites this paper
• Cardiovascular Outcomes with Liraglutide: An Update following LEADER

  2017cites this paper
• PAI-1 in Myocardial Remodeling: Is Pharmacological Suppression by ARB Beneficial?

  2016cites this paper
• Response by Ifergane et al to Letter Regarding Article, "Obstructive Sleep Apnea in Acute Stroke: A Role for Systemic Inflammation".

  2016cites this paper
• Treatment with oestrogen‐receptor agonists or oxytocin in conjunction with exercise protects against myocardial infarction in ovariectomized rats

  2016cites this paper